- Home
- RXRX vs MIRM Comparison
RXRX vs MIRM Comparison
Compare RXRX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- MIRM
- Stock Information
- Founded
- RXRX 2013
- MIRM 2018
- Country
- RXRX United States
- MIRM United States
- Employees
- RXRX N/A
- MIRM N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- MIRM Health Care
- Exchange
- RXRX Nasdaq
- MIRM Nasdaq
- Market Cap
- RXRX 2.6B
- MIRM 2.0B
- IPO Year
- RXRX 2021
- MIRM 2019
- Fundamental
- Price
- RXRX $7.21
- MIRM $42.04
- Analyst Decision
- RXRX Buy
- MIRM Strong Buy
- Analyst Count
- RXRX 5
- MIRM 11
- Target Price
- RXRX $9.25
- MIRM $57.00
- AVG Volume (30 Days)
- RXRX 16.7M
- MIRM 376.0K
- Earning Date
- RXRX 02-25-2025
- MIRM 02-26-2025
- Dividend Yield
- RXRX N/A
- MIRM N/A
- EPS Growth
- RXRX N/A
- MIRM N/A
- EPS
- RXRX N/A
- MIRM N/A
- Revenue
- RXRX $65,184,000.00
- MIRM $307,028,000.00
- Revenue This Year
- RXRX $60.17
- MIRM $82.14
- Revenue Next Year
- RXRX $19.88
- MIRM $26.18
- P/E Ratio
- RXRX N/A
- MIRM N/A
- Revenue Growth
- RXRX 37.64
- MIRM 112.14
- 52 Week Low
- RXRX $5.60
- MIRM $23.14
- 52 Week High
- RXRX $15.74
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- RXRX 52.64
- MIRM 47.79
- Support Level
- RXRX $6.65
- MIRM $40.91
- Resistance Level
- RXRX $7.86
- MIRM $42.40
- Average True Range (ATR)
- RXRX 0.64
- MIRM 1.45
- MACD
- RXRX -0.00
- MIRM -0.13
- Stochastic Oscillator
- RXRX 66.32
- MIRM 51.04
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.